Last reviewed · How we verify
4.4x10^8 TCID50s MVA-BN® Filo
4.4x10^8 TCID50s MVA-BN® Filo is a Biologic drug developed by University of Oxford. It is currently in Phase 1 development.
At a glance
| Generic name | 4.4x10^8 TCID50s MVA-BN® Filo |
|---|---|
| Sponsor | University of Oxford |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 4.4x10^8 TCID50s MVA-BN® Filo CI brief — competitive landscape report
- 4.4x10^8 TCID50s MVA-BN® Filo updates RSS · CI watch RSS
- University of Oxford portfolio CI
Frequently asked questions about 4.4x10^8 TCID50s MVA-BN® Filo
What is 4.4x10^8 TCID50s MVA-BN® Filo?
4.4x10^8 TCID50s MVA-BN® Filo is a Biologic drug developed by University of Oxford.
Who makes 4.4x10^8 TCID50s MVA-BN® Filo?
4.4x10^8 TCID50s MVA-BN® Filo is developed by University of Oxford (see full University of Oxford pipeline at /company/university-of-oxford).
What development phase is 4.4x10^8 TCID50s MVA-BN® Filo in?
4.4x10^8 TCID50s MVA-BN® Filo is in Phase 1.
Related
- Manufacturer: University of Oxford — full pipeline
- Compare: 4.4x10^8 TCID50s MVA-BN® Filo vs similar drugs
- Pricing: 4.4x10^8 TCID50s MVA-BN® Filo cost, discount & access